BRCA-mutated metastatic breast cancer

October 19, 2018

FDA Approves Talzenna to Treat BRCA-mutated Metastatic Breast Cancer

News

The U.S. Food and Drug Administration (FDA) has approved Pfizer’s Talzenna (talazoparib) for the treatment of HER2-negative advanced breast cancer in adult patients with inherited BRCA mutations. The FDA also stated that patients’ eligibility for ... Read more

April 4, 2018

EMA to Decide if Lynparza Can Treat BRCA-mutated Metastatic Breast Cancer Patients

News

The European Medicines Agency has agreed to review an application by AstraZeneca and MSD requesting the approval of Lynparza (olaparib) for the treatment of patients with a difficult-to-treat type of metastatic breast cancer who ... Read more

June 6, 2017June 6, 2017

Lynparza Shrinks Breast Cancer Tumors at Double the Rate of Chemo, Study Shows

News

The ovarian cancer therapy Lynparza (olaparib) shrank the tumors of 60 percent of breast cancer patients treated with it, double the figure for standard chemotherapy, according to a study. Lynparza, a PARP ... Read more

February 21, 2017

BRCA-mutated Breast Cancers May Benefit from Lynparza, a Therapy for Ovarian Cancer

News

The ovarian cancer drug Lynparza (olaparib) may be a promising treatment approach for patients with HER2-negative metastatic breast cancer who have BRCA1 and BRCA2 mutations, according to recent data from ... Read more